Acupan
(Nefopam)Phase 3Small molecule
Nefopam is a pain reliever used to treat moderate pain after surgery or injuries. It works differently than common painkillers like acetaminophen or ibuprofen.[1] Acupan is currently being investigated across 12 indications[3], with its most advanced program in Phase 3.[1]
Acupan is one of 189 small molecule programs targeting Lung Cancer. It is currently in Phase 3.
12
Indications
22
Total Trials
2
Active Trials
188
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Acupan
YYonsei University
Phase 3
Lexiscan
AstellasPreclinical
Voltaren
NovartisPreclinical
Zolymbus
AbbViePreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Spravato
WWim Janssens
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Analgesic2 trials
Prevention2 trials
Patient-Controlled Analgesia1 trial
Critically Ill Patients1 trial
Adjuvant Continuous Infusion of Nefopam Versus Standard of Care in Mechanically Ventilated Critically Ill Patients: Randomized Double-blind Controlled Study
Completed·—·Phase 3·NCT05071352·60 enrolled
15 more indications
Postoperative Analgesia1 trial
Acute Postoperative Pain1 trial
Intraoperative1 trial
Post Operative Pain1 trial
Total Hip Arthroplasty1 trial
Spinal Anesthesia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Nefopam. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- YYonsei University